Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies

Inclusion criteria

• Participants voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up.
• 18~80 years old.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• With evaluable tumor lesion.
• Relapsed and/or refractory hematologic malignancies (Non-Hodgkin Lymphoma or Multiple Myeloma).
• Life expectancy≥ 3 months.
• Clinical laboratory values meet screening visit criteria.
• Adequate organ function.

Exclusion criteria

• Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy.
• Prior antitumor therapy with insufficient washout period.
• Known life-threatening allergic reaction, hypersensitivity reaction, or intolerance to study drug excipients and related excipients, including but not limited to DMSO; or those with a history of severe allergic reactions in the past (such as hypersensitivity reactions, or those with severe immune-related reactions such as the need for glucocorticoids to prevent anaphylaxis as assessed by the investigator).
• Lactating women.